Placing in-vitro heteroresistance in the context of clinical results
Lancet Infect Dis
.
2021 Jul;21(7):908-909.
doi: 10.1016/S1473-3099(21)00328-5.
Authors
Matteo Bassetti
1
,
Roger Echols
2
,
Andrew Koren
3
,
Andreas Karas
4
,
Chris Longshaw
5
,
Yoshinori Yamano
6
,
Tsutae Den Nagata
6
Affiliations
1
Infectious Diseases Clinic, Department of Health Sciences, University of Genoa, Genoa and Hospital Policlinico San Martino IRCCS, Genoa, Italy.
2
Infectious Disease Drug Development Consulting, Easton, CT, USA.
3
Shionogi, Florham Park, NJ, USA.
4
Shionogi Europe, London WC2B 6UF, UK.
5
Shionogi Europe, London WC2B 6UF, UK. Electronic address:
[email protected]
.
6
Shionogi, Osaka, Japan.
PMID:
34174228
DOI:
10.1016/S1473-3099(21)00328-5
No abstract available
Publication types
Letter
Comment
MeSH terms
Anti-Bacterial Agents* / therapeutic use
Humans
Microbial Sensitivity Tests
Substances
Anti-Bacterial Agents